Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tokyo University | OTHER |
Not provided
Not provided
Not provided
Not provided
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China).
The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Overall survival (OS) is defined as the time (days) from the date of unresectable HCC diagnosis to the date of death, due to any reason. Patients alive or lost to follow-up at the time of analysis will be censored at their last date of follow-up | Up to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival (PFS) | Progression-free survival (PFS) is defined as the time (days) from the start of treatment to the date of first observed disease progression (radiological or clinical, whichever is earlier) or death due to any cause, if death occurs before progression is documented | Up to 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with Unresectable HCC who are treated under real-life clinical practice conditions in Asian Pacific Region
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Danny Wang, PhD | Contact | +852-21160598 | danny.wang@hnhmgl.com |
| Name | Affiliation | Role |
|---|---|---|
| Masao Omata, PhD, MD | Tokyo University | Study Chair |
| George Lau, MD | Humanity & Health Medical Group Limited | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing 302 Hospital | Recruiting | Beijing | China |
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| Time to progression (TTP) |
Time to progression (TTP) is defined as the time (days) from the start of treatment to the first documented disease progression |
| Up to 5 years |
| Duration of treatment | Duration of treatment, defined by the time interval from the start of treatment to the day of permanent discontinuation of treatment (including death) | Up to 5 years |
| Frequency and Severity of Adverse Events | Safety will be evaluated by monitoring and recording the grade 3, 4 and 5 adverse events (AE) occurring during and after treatment throughout follow up of patients. | Up to 5 years |
| Humanity & Health Medical Group Limited | Recruiting | Hong Kong | Hong Kong |
|
| Tokyo University | Recruiting | Tokyo | Japan |
|
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |